Recently, the centralized procurement platform for drugs and medical consumables in Gansu Province issued a notice that after receiving an application from an enterprise, 97 of the 53 registration certificates of the external diagnostic reagent products took the initiative to apply for a price reduction (Daan Gene), of which 12 new declaration registration certificates were reviewed and passed
in accordance with the "green channel".
The adjusted price shall be used as the highest reference price in the province for medical institutions to negotiate and purchase, and other enterprises are encouraged to take the initiative to apply for price adjustment to a reasonable level
.
This is not the first time that Daan Gene has significantly reduced the terminal price
of its molecular diagnostic reagent products.
It is understood that the Qinghai Provincial Drug Procurement Center issued the "Notice on Adjusting the Price of Some Medical Consumables Reagents"
on November 15.
According to the "Notice", the median decline rate of 39 molecular diagnostic products under Daan Gene has reached 76.
85%, and the decline rate of 4 products has exceeded 90%.
Among them, the product with the largest decrease was hepatitis B virus genotyping test kit (PCR-reverse point hybridization), which was previously priced at 185 yuan per person in Beijing; Today, the price in Qinghai Province has dropped to 10 yuan per person
.
In fact, in September 2021, Anhui initiated the collective procurement of in vitro diagnostic chemiluminescence reagents, and the negotiation results showed that 12 of the 13 companies participating in the negotiation successfully won the bid, and the average price of the product was reduced by 47%.
From the current point of view, the reduction rate of Daan Gene's price adjustment has exceeded that of centralized procurement
.
In this regard, there is a view that Daan Gene launched a "centralized procurement" attack
on the entire molecular diagnostic industry in an active way.
After all, at present, the national recruitment and procurement has basically formed a chess game, after Da'an takes a step ahead, one enterprise moves, it is difficult not to affect other enterprises
.
In addition to medical consumables, in recent years, under the pressure of the market and policies, a large number of pharmaceutical companies have actually begun to actively reduce prices
in various places.
On August 9 this year, the Sichuan Provincial Centralized Procurement Platform for Pharmaceuticals and Devices issued a notice
on the price reduction of a large number of drugs.
According to the notice, according to the application for drug price reduction submitted by enterprises on the Sichuan Provincial Centralized Procurement of Drugs and Devices and Pharmaceutical Price Supervision Platform, it is proposed to reduce the linkage reference prices
of some drugs.
Among them, Hunan Dino Pharmaceutical Co.
, Ltd.
applied for price reduction in 13 batches of products, including clopidogrel hydrogen sulfate tablets (6 specifications), triamcinolone acetonide iconazole cream, atorvastatin calcium tablets (6 specifications).
On July 26, the Shanxi Provincial Centralized Bidding and Procurement Network for Pharmaceuticals and Devices issued a notice
on drug price adjustment.
The notice shows that according to the application of enterprises, the online prices of 9 drugs of 7 enterprises including Guangdong Dongguang Pharmaceutical Co.
, Ltd.
will be adjusted
.
The seven pharmaceutical companies include Guangdong Dongguang Pharmaceutical Co.
, Ltd.
, Yueyang Xinhuada Pharmaceutical Co.
, Ltd.
, Shanxi Renyuantang Pharmaceutical Co.
, Ltd.
, Tianjin Weiming Biopharmaceutical Co.
, Ltd.
, Jiangsu Hengrui Pharmaceutical Co.
, Ltd.
, Tianjin Takeda Pharmaceutical Co.
, Ltd.
, Fresenius Kabi Austria GmbH Fresenius Kabi Group (Austria).
The drugs involved include Clarithromycin tablets, banbuterol hydrochloride oral solution, vascular rehabilitation tablets, human interferon α2b spray, gadolinate glucosamine injection, voglibose tablets, propofol emulsion injection and other 9 drugs
.
On February 21, the Yunnan Provincial Drug Centralized Procurement Platform issued a public notice
on enterprises applying for price reductions.
According to the notice, the Yunnan Provincial Procurement Center received voluntary price reduction applications from 21 enterprises, including Shanghai Pharmaceutical Holdings, Chia Tai Tianqing, Jiangsu Haosen, and CSPC Pharmaceutical Group, and reduced the price
of 78 drugs such as denogestrel tablets, amoxicillin, clavulanate potassium tablets, risedronate sodium tablets, penicillin V potassium tablets, paclitaxel injection, and lenvatinib mesylate capsules.
.
.
.
.
.
.
With the continuous advancement of national centralized procurement, in the case of intensifying market competition, whether it is drugs or medical consumables, price reduction will become the general trend
.
In the future, more and more pharmaceutical companies, especially those with supply chain advantages, may take such measures one after another, and actively seek price reductions in more cities to cover more markets
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
